Alzheimer
Stay current with all the latest and breaking news from Alzheimer, compare headlines and perspectives between news sources on stories happening today. In total, 589 stories have been published about Alzheimer which Ground News has aggregated in the past 3 months.Media Bias Breakdown
How is the media covering Alzheimer?Alzheimer often is covered by Center Media sources.
25%
Center: 59%
16%
Stay current with all the latest and breaking news from Alzheimer, compare headlines and perspectives between news sources on stories happening today. In total, 589 stories have been published about Alzheimer which Ground News has aggregated in the past 3 months.
Location of Coverage About AlzheimerBased on 589 recent stories
21% Local Coverage66% National Coverage13% International Coverage
Media Bias Breakdown
How is the media covering Alzheimer?Alzheimer often is covered by Center Media sources.
25%
Center: 59%
16%
Alzheimer's Association
@alzassociation82% LEFT
18%
Top Alzheimer News
Asia · TokyoAn experimental Alzheimer's drug developed by Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the companies said on Tuesday.See the Story
'Historic moment' in Alzheimer's treatment as trial drug found to slow cognitive decline
58% Center coverage: 138 sources
BusinessBiogen and Japanese drugmaker Eisai announced their experimental Alzheimer's medication lecanemab met the main goal in a large-stage trial. The treatment was found to have cut the cognitive and functional decline of patients with early stage of the disease by 27%, compared to placebo, over 18 months. Eli Lilly (LLY), and Roche (OTCQX:RHHBY) have added ~8% and ~5%, respectively.See the Story
Biogen shares soar on landmark Alzheimer's data, lift rivals
83% Center coverage: 6 sources
Alzheimer's DiseaseShares of Biogen Inc. jumped 40% to close Wednesday at $276.61. Eisai Co. Ltd. said it would discuss full results from the research at a conference in late November. The company is already seeking an accelerated approval from the U.S. Food and Drug Administration.See the Story
Alzheimer’s drug shows promise in early results of study
75% Center coverage: 4 sources
Latest News Stories
Alzheimer's Disease · The CrossingsThe bright flowers symbolic of the fight to end Alzheimer's disease will adorn The Crossings of Colonie on Saturday for the annual Walk to End Alzheimers.See the Story
Walk to End Alzheimer’s on tap at Crossings park
100% Center coverage: 1 sources
AlzheimerAlzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s TypeSee the Story
Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study - Alzamend Neuro (NASDAQ:ALZN)
100% Center coverage: 1 sources
Business · BostonBiogen Inc. has spent much of the past year shedding assets following the disastrous rollout of its first Alzheimer's disease drug. Now, a new Alzheimer's drug could turn things around and allow the Cambridge company to plan for growth again. Positive topline data from a new drug called lecanemab, which Japanese drugmaker Eisai Inc. largely developed with Biogen as its partner, has sent Biogen's shares skyrocketing.See the Story
Five questions around Biogen in wake of the new Alzheimer's drug data
Coverage: 2 sources
Alzheimer's Disease · SydneyAn overseas study has shown that Lecanemab can reduce cognitive decline by 27 per cent compared to placebo. The drug works by removing the build-up of amyloid plaques in the brain which is one of the hallmarks of the disease. More than 1700 patients with mild cognitive impairment were enrolled in the study.See the Story
Trial drug shows 'significant' results in slowing down Alzheimer's disease
100% Right coverage: 1 sources
AlzheimerEisai Co, a Tokyo-based pharmaceutical company with a family bent and market capitalisation of $14 billion, crossed the finish line before behemoths valued nearly 20-fold higher, including industry leaders Roche Holding AG and Eli Lilly & CoSee the Story
At last, a drug to slow down Alzheimer's
100% Right coverage: 1 sources
AlzheimerThe discovery of a drug able to slow cognitive decline in early-stage Alzheimer’s is being called a ‘historic moment’ in the treatment of the disease.See the Story
Tech & Science Daily: ‘Historic moment’ in Alzheimer’s treatment
100% Right coverage: 1 sources
FDAThe drop in 2023 Medicare premiums could soon be reversed, however, if Biogen’s new Alzheimer’s drug lecanemab gains FDA approval.See the Story
Medicare Part B premiums to drop 3% next year, partly due to limited Aduhelm coverage
Alzheimer · Bowling GreenMan arrested on suspicion of driving under the influence in Bowling Green. Police found bottle of prescription pills in the vehicle. Driver faces charges of operating a motor vehicle under the Influence of alcohol. He also faces a charge of operating on a suspended or revoked license. He was taken to the Warren County Detention Center.See the Story
